Table 1 Baseline characteristics of study patients considered as a whole and by achievement of ID
Features | All patients (n = 375) | Patients who did not achieve ID (n = 146) | Patients who achieved ID (n = 229) | P# |
|---|---|---|---|---|
Gender | 0.0004 | |||
Female | 299 (79.7) | 103 (70.5) | 195 (85.6) | |
Male | 76 (20.3) | 43 (29.5) | 33 (14.4) | |
Median (IQR) age at disease onset, yrs | 3.2 (1.7–7.0) | 4.4 (1.9–8.2) | 2.7 (1.7–5.5) | 0.002 |
Median (IQR) age, yrs | 5.6 (3.0–9.5) | 6.3 (3.3–9.9) | 4.9 (2.8–9) | 0.05 |
Median (IQR) disease duration, yrs | 0.8 (0.4–2.4) | 0.8 (0.3–2.5) | 0.9 (0.4–2.4) | 0.08 |
Median (IQR) follow-up time, yrs | 1.5 (0.8–2.5) | 1.2 (0.5–2.6) | 1.7 (1–2.5) | 0.002 |
Functional phenotypes§ | < 0.0001 | |||
Systemic arthritis | 29/373 (7.8) | 25 (17.2) | 4 (1.8) | |
Polyarthritis | 151/373 (40.5) | 59 (40.7) | 92 (40.3) | |
Oligoarthritis | 174/373 (46.6) | 49 (33.8) | 125 (54.8) | |
Enthesitis-related arthritis | 19/373 (5.1) | 12 (8.3) | 7 (3.1) | |
Patients with positive ANA | 264/371 (71.2) | 79/133 (59.4) | 185/226 (81.9) | < 0.0001 |
Median (IQR) no. of active joints | 5 (3–8) | 5 (3–10) | 5 (3–7) | 0.51 |
Median (IQR) ESR, mm/h (n = 313) | 40 (21–58) | 46 (24–62) | 35.5 (19–56) | 0.02 |
Median (IQR) CRP, mg/dl (n = 315) | 1.3 (0.5–3.6) | 2 (0.5–4.4) | 0.9 (0.5–3) | 0.001 |